FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients
The new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to a new treatment.
Free to read, from the publishers who wrote it. We carry the headline and send you to the source. Beside it sits the one story nobody else can report: what changed on the board in the last day, taken straight from the ledger.
Up 1 places, from #40 to #39.
Up 1 places, from #39 to #38.
Up 1 places, from #38 to #37.
Up 1 places, from #37 to #36.
Up 1 places, from #36 to #35.
Up 1 places, from #35 to #34.
The new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to a new treatment.
Gap announced a new CEO for Old Navy on Thursday as the brand reported a decline in comparable sales for the most recent quarter.
Headlines and links belong to the publishers named beside them. We reproduce no article text. Every source is listed.